The following image of the natural history of MS indicates the significant amount of MRI activity that occurs in the pre-clinical phase and early relapsing-remitting MS, the gradual decrease in inflammatory attacks (relapses) over time, and the increasing MRI burden of disease that occurs along with a decrease in brain volume. This schematic supports the role of DMTs early in the disease course.
Explaining to patients and family members about the purpose of disease-modifying therapies in MS management (Rio et al., 2005)
Setting realistic expectations for the treatment; unrealistic expectations are a common reason why patients discontinue their medication (Mohr et al., 1996).
Instructing patients on proper use of a medication, particularly injection techniques and rotation regimens to minimize skin reactions with injectable medications (Saunders et al., 2010; Webb, 2008).
Monitoring for side effects and providing management strategies; inadequate management of side effects is another key reason why people discontinue their medication (Webb, 2008).